Your session is about to expire
← Back to Search
Observational (genetic analysis) for Childhood Cancer
N/A
Recruiting
Led By Smita Bhatia
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Summary
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Eligible Conditions
- Childhood Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Crude disease-exposure
Frequency of mutations or polymorphisms in specific candidate genes in cases and controls
Rate of adverse events (cardiac dysfunction, AVN, ischemic stroke, and SMN using a matched case-control)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (genetic analysis)Experimental Treatment2 Interventions
DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,841 Previous Clinical Trials
40,998,930 Total Patients Enrolled
Children's Oncology GroupLead Sponsor
457 Previous Clinical Trials
235,945 Total Patients Enrolled
Smita BhatiaPrincipal InvestigatorChildren's Oncology Group
3 Previous Clinical Trials
6,290 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger